Evidence map›Paper›PMID 27766568›Full record

ReviewJournal of nephrology2016

ADPKD: clinical issues before and after renal transplantation.

Piergiorgio Messa, Carlo Maria Alfieri, Emanuele Montanari, Mariano Ferraresso, Roberta Cerutti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Piergiorgio MessaFondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico di Milano, Università agli studi di Milano, Area Omogenea Nefro-Urologica e Trapianto di Rene, Milan, Italy. pmessa@policlinico.mi.it.ORCID http://orcid.org/0000-0002-1512-559X
Carlo Maria AlfieriFondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico di Milano, Università agli studi di Milano, Area Omogenea Nefro-Urologica e Trapianto di Rene, Milan, Italy.
Emanuele MontanariFondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico di Milano, Università agli studi di Milano, Area Omogenea Nefro-Urologica e Trapianto di Rene, Milan, Italy.
Mariano FerraressoFondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico di Milano, Università agli studi di Milano, Area Omogenea Nefro-Urologica e Trapianto di Rene, Milan, Italy.
Roberta CeruttiFondazione Ca' Granda IRCCS Ospedale Maggiore Policlinico di Milano, Università agli studi di Milano, Area Omogenea Nefro-Urologica e Trapianto di Rene, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the first genetic cause of end-stage renal disease (ESRD) and the number of these patients who are listed for or receive a kidney transplant (KTx) is continuously increasing over time. Hence, nephrologists are involved not only in the handling of ADPKD patients during the long course of the disease, but also in programming and performing a renal transplant. The handling of all these processes implies the complete awareness of a number of critical points related to the decisions to be taken both before and after the transplant intervention. In the present review, we will briefly deal with the main critical points related to the clinical handling of the patients both before and after KTx.

Indexed as

Kidney TransplantationClinical Decision-MakingDisease ProgressionGraft SurvivalHumansKidney Failure, ChronicNephrologistsPatient SelectionPolycystic Kidney, Autosomal DominantPostoperative ComplicationsProfessional RoleRisk FactorsTime FactorsTreatment Outcome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.